Literature DB >> 6205994

Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule.

W A Volk, B Bizzini, R M Snyder, E Bernhard, R R Wagner.   

Abstract

Fifty-seven hybridomas producing antibodies to tetanus toxoid or to the Ibc or B-IIb fragment of the toxin were isolated independently. Competitive inhibition studies demonstrated that monoclonal antibodies from mice immunized with the toxoid bound to at least 20 different epitopes on the toxoid molecule. Similar competitive binding studies revealed eight distinct epitopes on the B-IIb fragment and three to five epitopes on the Ibc fragment of the toxin. Neutralization of toxicity was effected by nine distinct monoclonal antibodies from hybridomas of toxoid-immunized mice and by one monoclonal antibody from B-IIb-immunized mice. Mixtures of two, three, and four different monoclonal antibodies in a variety of combinations exerted a synergistic effect of ca. 200-fold over that observed with individual monoclonal antibodies, indicating that efficient neutralization may involve the simultaneous binding of at least two antibody molecules to different specific regions of the toxin molecule. Only one toxoid-induced monoclonal antibody failed to bind to tetanus toxin. All neutralizing antibodies bound to epitopes on the heavy chain of tetanus toxin. Six of these were directed toward epitopes on the NH2-terminal half, whereas four bound to epitopes on the carboxy-terminal half of the heavy chain. Only one monoclonal antibody bound preferentially to the light chain, but two other monoclonal antibodies appeared to bind to both chains, indicating some homology between these two chains.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6205994      PMCID: PMC263337          DOI: 10.1128/iai.45.3.604-609.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

Review 2.  Tetanus toxin.

Authors:  B Bizzini
Journal:  Microbiol Rev       Date:  1979-06

3.  Studies on tetanus antitoxins. II. Demonstration of at least four antitoxins of different specificity in antitoxic sera.

Authors:  J Nagel; H Cohen
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

4.  Use of the B-IIb tetanus toxin derived fragment as a specific neuropharmacological transport agent.

Authors:  B Bizzini; P Grob; M A Glicksman; K Akert
Journal:  Brain Res       Date:  1980-07-07       Impact factor: 3.252

5.  Isolation and purification of two antigenically active, "complimentary" polypeptide fragments of tetanus neurotoxin.

Authors:  M Matsuda; M Yoneda
Journal:  Infect Immun       Date:  1975-11       Impact factor: 3.441

6.  An antigenic polypeptide fragment isolated from tetanus toxin: chemical characterization, binding to gangliosides and retrograde axonal transport in various neuron systems.

Authors:  B Bizzini; K Stoeckel; M Schwab
Journal:  J Neurochem       Date:  1977-03       Impact factor: 5.372

7.  Preparation of conjugates using two tetanus toxin derived fragments: their binding to gangliosides and isolated synaptic membranes and their immunological properties.

Authors:  B Bizzini; K Akert; M Glicksman; P Grob
Journal:  Toxicon       Date:  1980       Impact factor: 3.033

8.  Antigenic substructure of tetanus neurotoxin.

Authors:  M Matsuda; M Yoneda
Journal:  Biochem Biophys Res Commun       Date:  1977-07-11       Impact factor: 3.575

9.  Replacement of the international standard for tetanus antitoxin and the use of the standard in the flocculation test.

Authors:  J Spaun; J Lyng
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

10.  Production and characterization of monoclonal antibodies to tetanus toxin.

Authors:  A J Sheppard; D Cussell; M Hughes
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

View more
  33 in total

1.  Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice.

Authors:  Joseph S Zakhari; Eric P Zorrilla; Bin Zhou; Alexander V Mayorov; Kim D Janda
Journal:  Mol Pharm       Date:  2011-12-23       Impact factor: 4.939

2.  Folding domains within the ricin toxin A subunit as targets of protective antibodies.

Authors:  Joanne M O'Hara; Lori M Neal; Elizabeth A McCarthy; Jane A Kasten-Jolly; Robert N Brey; Nicholas J Mantis
Journal:  Vaccine       Date:  2010-08-18       Impact factor: 3.641

Review 3.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

4.  Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin.

Authors:  S F Little; S H Leppla; E Cora
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

5.  Enzymatic hydrolysis of tetanus toxin by intrinsic and extrinsic proteases. Characterization of the fragments by monoclonal antibodies.

Authors:  K Goretzki; E Habermann
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

6.  Relation between protective potency and specificity of antibodies in sera of tetanus immunized individuals.

Authors:  M German-Fattal; A German; B Bizzini
Journal:  Eur J Epidemiol       Date:  1987-06       Impact factor: 8.082

7.  Polyspecific human and murine antibodies to diphtheria and tetanus toxoids and phospholipids.

Authors:  M Sutjita; A Hohmann; R Comacchio; J Bradley
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

8.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

9.  Preferential use of DH reading frame 2 alters B cell development and antigen-specific antibody production.

Authors:  Robert L Schelonka; Michael Zemlin; Ryoki Kobayashi; Gregory C Ippolito; Yingxin Zhuang; G Larry Gartland; Alex Szalai; Kohtaro Fujihashi; Klaus Rajewsky; Harry W Schroeder
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

10.  Characterisation of a panel of anti-tetanus toxin single-chain Fvs reveals cooperative binding.

Authors:  Nathan Scott; Omar Qazi; Michael J Wright; Neil F Fairweather; Mahendra P Deonarain
Journal:  Mol Immunol       Date:  2010-04-22       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.